

## **News Release**

February 1, 2008

# Astellas Announces Revision of Dividend Forecast for FY2007 (3rd Company Fiscal Period)

Japan, February 1, 2008 – Astellas Pharma Inc. ("the Company", headquarters: Tokyo, President and CEO: Masafumi Nogimori) announced that at the meeting of the Board of Directors held today, a resolution was adopted a revision of dividend forecast for fiscal year 2007, ending March 2008 as below:

#### **Particulars**

#### 1. Reasons for Revision

The Company is committed to sustained improvement in its enterprise value, leading to improved return to shareholders. While putting priority on investment to assure future growth, the Company will continuously increase dividend payments assuming improvement in medium- to long-term earnings on a consolidated basis, and also implement share buybacks in a flexible manner to improve capital efficiency and raise the level of return to shareholders. Based on these policies, the Company has a medium-term DOE (dividend on equity) target of 8% in the fiscal year ending March 31, 2011 (FY2010).

In consideration of the policies discussed above, consolidated business forecasts and financial condition, the Company revised its year-end dividend forecast to \\$60 per share to shareholders, up \\$10 compared to the previous forecast. As a result, dividend was revised to \\$110 per share (including interim dividend of \\$50 per share), up \\$30 per share compared to the previous fiscal year.

### 2. Contents of Revision

	Dividends per share		
	Interim	Year-end	Annual Total
Previous forecast (Announced on May 15, 2007)	¥50.00	¥50.00	¥100.00
FY2007 forecast	¥50.00	¥60.00	¥110.00
FY2007 (Actual payout)	¥50.00		
FY2006	¥40.00	¥40.00	¥80.00

#### ######

Contacts for inquiries or additional information

Astellas Pharma Inc.

**Corporate Communications** 

Tel: +81-3-3244-3201 Fax: +81-3-5201-7473

http://www.astellas.com